Arkal Medical is developing a continuous blood glucose sensor for diabetes.

Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. Vytrace Corporation is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.

Located in Hanover, NH and San Francisco, CA, Novoculi is a medical device company focused on developing a non-invasive, optical blood glucose monitor. Novoculi's Noninvasive Blood Glucose Monitor aims to build on physiologically demonstrated optical phenomena which forms the basis for Novoculi's technology. Novoculi hopes to leverage its technology to develop a non-invasive blood glucose monitor which will allow its patient population to better manage their blood glucose without a painful finger stick.

Advanced BioSensors is developing a miniaturized blood glucose sensor for use in the treatment of diabetes.

Vytrace Corporation (fka Glucose Sensing Technologies) is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.

Bay Area Digital is a company that received a SBIR Phase I grant for a project entitled: Talking Blood Glucose Meter with full Accessibility for Blind, Visually and Cognitively Impaired. Their Project addresses a crisis in the lack of effective glucose monitoring equipment for visually and cognitively impaired diabetics. The proposal thoroughly examines the technical and commercial feasibility of developing innovative technology that enables such patients to reliably use information provided by a state-of-the-art blood glucose meter, using speech output that is coupled with a commercially developed meter. There are currently no state-of-the-art or best-of-breed blood glucose meter systems available in the U.S. market with speech capabilities for use by the cognitively, visually impaired or blind community. The development of such a meter will positively impact the self-management of diabetes mellitus, improving quality of life and clinical outcomes for patients and preventing the development of secondary complications and provide an opportunity to impact a major health problem affecting millions of U.S. citizens.